OC
RPTP

Oppenheimer & Co’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Oppenheimer & Co’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-23,282
Closed -$218K – 1447
2013
Q2 		$218K Buy
+23,282
New +$158K 0.01% 1069

Other funds holding RPTP

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Oppenheimer & Co's RPTP Position: Q3 2013 in Review

Oppenheimer & Co sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2013, closing a stake of 23,282 shares — an estimated $218K sold.

Oppenheimer & Co first reported a position in RPTP in Q2 2013 and held it in 1 quarter. The position peaked at $218K in Q2 2013. 71 funds tracked by Wall St. Rank hold RPTP as of Q3 2013.

  • Oppenheimer & Co reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 23,282 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2013, an estimated $218K.
  • Oppenheimer & Co first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Oppenheimer & Co's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $218K in Q2 2013.
  • 71 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2013.

Based on Oppenheimer & Co's 13F filing for Q3 2013, filed 1 Nov 2013.